Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors

Ashley N. Matthew, Jacqueto Zephyr, Desaboini Nageswara Rao, M. Henes, Wasih Kamran, K. Kosovrasti, Adam K. Hedger, G.J. Lockbaum, Jennifer Timm, Akbar Ali,

mBio · 2020 · 26 citations · 51 references

DOIFull text

Open access

Concepts

Abstract

Despite significant progress, hepatitis C virus (HCV) continues to be a major health problem with millions of people infected worldwide and thousands dying annually due to resulting complications. Recent antiviral combinations can achieve >95% cure, but late diagnosis, low access to treatment, and treatment failure due to drug resistance continue to be roadblocks against eradication of the virus. We report the rational design of two series of HCV NS3/4A protease inhibitors with improved resistance profiles by exploiting evolutionarily constrained regions of the active site using the substrate envelope model. Optimally filling the S4 pocket is critical to avoid resistance and improve potency. Our results provide drug design strategies to avoid resistance that are applicable to other quickly evolving viral drug targets.

References

51